Physician Support
Androgen Reduction Graph		  
 

Androgen reduction success rate was 99 percent, as proven in clinical trials.

  • Testosterone was below the castrate threshold between weeks 2 and 4 in 99 percent of patients, following the expected initial increase. As a result of this increase, prostate cancer-related symptoms may become worse during the first few weeks of treatment.

  • Once reduced, testosterone remained well below the castrate threshold for the duration of the treatment.

  • Reduction was maintained following removal and insertion of a new implant with no rise in testosterone.
Testosterone Reduction Graph

Androgen Suppression Graph

  

Important Safety Considerations
Viadur should not be used by patients who are allergic to the drug leuprolide. Viadur should not be used by women or children and was not studied in women or children. Viadur, like other similar medications, causes a temporary increase of testosterone in the blood during the first week of treatment. During this initial period, patients may experience worsening of symptoms or onset of new symptoms including bone pain, nervous system distribances, blood in the urine, difficulty urinating, and spinal cord compression. During treatment, the most common side effects reported throughout the body were hot flashes, lack of energy, breast enlargement, depression, and sweating. The most common side effects reported where the implant was inserted in the arm were bruising and burning.

See Your Healthcare Provider
Remember, your doctor or health care provider is the single best source of information regarding you and your health. Please consult your doctor if you have any questions about your health, your symptoms, or your medication.

This information does not take the place of your doctor’s advice or instructions but should help answer some of the questions you might have about prostate cancer therapies.
Distributed and Marketed by: Manufactured by:

Bayer HealthCare Pharmaceuticals
6 West Belt, Wayne, NJ 07470 USA

© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation.

The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.